PET/CT in therapy evaluation of patients with lung cancer

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

PET/CT in therapy evaluation of patients with lung cancer. / Langer, Natasha Hemicke; Christensen, Tine Nøhr; Langer, Seppo W; Kjaer, Andreas; Fischer, Barbara Malene.

I: Expert Review of Anticancer Therapy, Bind 14, Nr. 5, 2014, s. 595-620.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Langer, NH, Christensen, TN, Langer, SW, Kjaer, A & Fischer, BM 2014, 'PET/CT in therapy evaluation of patients with lung cancer', Expert Review of Anticancer Therapy, bind 14, nr. 5, s. 595-620. https://doi.org/10.1586/14737140.2014.883280

APA

Langer, N. H., Christensen, T. N., Langer, S. W., Kjaer, A., & Fischer, B. M. (2014). PET/CT in therapy evaluation of patients with lung cancer. Expert Review of Anticancer Therapy, 14(5), 595-620. https://doi.org/10.1586/14737140.2014.883280

Vancouver

Langer NH, Christensen TN, Langer SW, Kjaer A, Fischer BM. PET/CT in therapy evaluation of patients with lung cancer. Expert Review of Anticancer Therapy. 2014;14(5):595-620. https://doi.org/10.1586/14737140.2014.883280

Author

Langer, Natasha Hemicke ; Christensen, Tine Nøhr ; Langer, Seppo W ; Kjaer, Andreas ; Fischer, Barbara Malene. / PET/CT in therapy evaluation of patients with lung cancer. I: Expert Review of Anticancer Therapy. 2014 ; Bind 14, Nr. 5. s. 595-620.

Bibtex

@article{8a17c044e6c541349b77f35862002ba5,
title = "PET/CT in therapy evaluation of patients with lung cancer",
abstract = "FDG-PET/CT is a well documented and widespread used imaging modality for the diagnosis and staging of patient with lung cancer. FDG-PET/CT is increasingly used for the assessment of treatment effects during and after chemotherapy. However, PET is not an accepted surrogate end-point for assessment of response rate in clinical trials. The aim of this review is to present current evidence on the use of PET in response evaluation of patients with lung cancer and to introduce the pearls and pitfalls of the PET-technology relating to response assessment. Based on this and relating to validation criteria, including stable technology, standardization, reproducibility and broad availability, the review discusses why, despite numerous studies on response assessment indicating a possible role for FDG-PET/CT, PET still has no place in guidelines relating to response evaluation in lung cancer.",
keywords = "Humans, Lung Neoplasms, Multimodal Imaging, Positron-Emission Tomography, Tomography, X-Ray Computed",
author = "Langer, {Natasha Hemicke} and Christensen, {Tine N{\o}hr} and Langer, {Seppo W} and Andreas Kjaer and Fischer, {Barbara Malene}",
year = "2014",
doi = "10.1586/14737140.2014.883280",
language = "English",
volume = "14",
pages = "595--620",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Taylor & Francis",
number = "5",

}

RIS

TY - JOUR

T1 - PET/CT in therapy evaluation of patients with lung cancer

AU - Langer, Natasha Hemicke

AU - Christensen, Tine Nøhr

AU - Langer, Seppo W

AU - Kjaer, Andreas

AU - Fischer, Barbara Malene

PY - 2014

Y1 - 2014

N2 - FDG-PET/CT is a well documented and widespread used imaging modality for the diagnosis and staging of patient with lung cancer. FDG-PET/CT is increasingly used for the assessment of treatment effects during and after chemotherapy. However, PET is not an accepted surrogate end-point for assessment of response rate in clinical trials. The aim of this review is to present current evidence on the use of PET in response evaluation of patients with lung cancer and to introduce the pearls and pitfalls of the PET-technology relating to response assessment. Based on this and relating to validation criteria, including stable technology, standardization, reproducibility and broad availability, the review discusses why, despite numerous studies on response assessment indicating a possible role for FDG-PET/CT, PET still has no place in guidelines relating to response evaluation in lung cancer.

AB - FDG-PET/CT is a well documented and widespread used imaging modality for the diagnosis and staging of patient with lung cancer. FDG-PET/CT is increasingly used for the assessment of treatment effects during and after chemotherapy. However, PET is not an accepted surrogate end-point for assessment of response rate in clinical trials. The aim of this review is to present current evidence on the use of PET in response evaluation of patients with lung cancer and to introduce the pearls and pitfalls of the PET-technology relating to response assessment. Based on this and relating to validation criteria, including stable technology, standardization, reproducibility and broad availability, the review discusses why, despite numerous studies on response assessment indicating a possible role for FDG-PET/CT, PET still has no place in guidelines relating to response evaluation in lung cancer.

KW - Humans

KW - Lung Neoplasms

KW - Multimodal Imaging

KW - Positron-Emission Tomography

KW - Tomography, X-Ray Computed

U2 - 10.1586/14737140.2014.883280

DO - 10.1586/14737140.2014.883280

M3 - Journal article

C2 - 24702537

VL - 14

SP - 595

EP - 620

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 5

ER -

ID: 139857094